BioCentury | Jun 30, 2020
Finance

Syncona’s Freeline mulls IPO after crossovers back gene therapy play

...£25 million in an initial 2015 round; Syncona provided almost all of that cash, with UCL Technology Fund...
BioCentury | Jun 5, 2020
Emerging Company Profile

Epsilogen: co-opting IgE antibodies against cancer

...partners: None Number of employees: 5 Funds raised: $10 million Investors: ASLA Ventures, Epidarex Capital, UCL Technology Fund...
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

...raised a £28.3 million ($36.3 million) series A round from Syncona, CRT Pioneer Fund and UCL Technology Fund...
BioCentury | May 31, 2019
Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

...£28.3 million ($36.3 million) series A round in 2016 from Syncona, CRT Pioneer Fund amd UCL Technology Fund...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...vivo gene therapy Endocrine/ metabolic, hematology, neurology Freeline Therapeutics Ltd. $117.0 Series B Syncona Ltd., UCL Technology Fund...
BioCentury | May 20, 2019
Financial News

Syncona launches Treg company Quell with £35 million A round

...transplant-related diseases. The firm supplied all but £1 million ($1.3 million) of the round, with UCL Technology Fund...
BioCentury | Jan 18, 2019
Emerging Company Profile

Achilles’ truncal neoantigens

...employees: 50 Funds raised: £28.3 million ($36.3 million) Investors: Syncona Ltd., CRT Pioneer Fund and UCL Technology Fund...
BioCentury | Jun 22, 2018
Financial News

Syncona leads Freeline's £88M series B

...B round which included £85 million from lead investor Syncona Ltd. (LSE:SYNC). Fellow founding investor UCL Technology Fund...
BioCentury | Jun 19, 2018
Financial News

Syncona leads Freeline's £88M series B

...B round which included £85 million from lead investor Syncona Ltd. (LSE:SYNC). Fellow founding investor UCL Technology Fund...
BioCentury | May 18, 2018
Finance

China comes to Europe

...U.K.) $110.0 Series B Temasek, F-Prime Capital , RTW Investments , Pavilion Capital, Baillie Gifford, UCL Technology Fund...
...Therapeutics Ltd. (U.K.) $110.0 Series B Temasek, F-Prime Capital, RTW Investments, Pavilion Capital, Baillie Gifford, UCL Technology Fund...
...Orchard raised $30.7 million in a series A round from founding investors F-Prime and the UCL Technology Fund...
Items per page:
1 - 10 of 28
BioCentury | Jun 30, 2020
Finance

Syncona’s Freeline mulls IPO after crossovers back gene therapy play

...£25 million in an initial 2015 round; Syncona provided almost all of that cash, with UCL Technology Fund...
BioCentury | Jun 5, 2020
Emerging Company Profile

Epsilogen: co-opting IgE antibodies against cancer

...partners: None Number of employees: 5 Funds raised: $10 million Investors: ASLA Ventures, Epidarex Capital, UCL Technology Fund...
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

...raised a £28.3 million ($36.3 million) series A round from Syncona, CRT Pioneer Fund and UCL Technology Fund...
BioCentury | May 31, 2019
Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

...£28.3 million ($36.3 million) series A round in 2016 from Syncona, CRT Pioneer Fund amd UCL Technology Fund...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...vivo gene therapy Endocrine/ metabolic, hematology, neurology Freeline Therapeutics Ltd. $117.0 Series B Syncona Ltd., UCL Technology Fund...
BioCentury | May 20, 2019
Financial News

Syncona launches Treg company Quell with £35 million A round

...transplant-related diseases. The firm supplied all but £1 million ($1.3 million) of the round, with UCL Technology Fund...
BioCentury | Jan 18, 2019
Emerging Company Profile

Achilles’ truncal neoantigens

...employees: 50 Funds raised: £28.3 million ($36.3 million) Investors: Syncona Ltd., CRT Pioneer Fund and UCL Technology Fund...
BioCentury | Jun 22, 2018
Financial News

Syncona leads Freeline's £88M series B

...B round which included £85 million from lead investor Syncona Ltd. (LSE:SYNC). Fellow founding investor UCL Technology Fund...
BioCentury | Jun 19, 2018
Financial News

Syncona leads Freeline's £88M series B

...B round which included £85 million from lead investor Syncona Ltd. (LSE:SYNC). Fellow founding investor UCL Technology Fund...
BioCentury | May 18, 2018
Finance

China comes to Europe

...U.K.) $110.0 Series B Temasek, F-Prime Capital , RTW Investments , Pavilion Capital, Baillie Gifford, UCL Technology Fund...
...Therapeutics Ltd. (U.K.) $110.0 Series B Temasek, F-Prime Capital, RTW Investments, Pavilion Capital, Baillie Gifford, UCL Technology Fund...
...Orchard raised $30.7 million in a series A round from founding investors F-Prime and the UCL Technology Fund...
Items per page:
1 - 10 of 28